Probability

Atomwise Publishes Results from 318-Target Study Showcasing AtomNet AI Platform’s Ability to Discover Structurally Novel Chemical Matter

Retrieved on: 
Tuesday, April 2, 2024
Research, Technology, Neurology, Health Technology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Artificial Intelligence, AIMS, Biochemistry, Disease, Executive, University, HTS, Patient, AI, Scientific Reports, OTUD7B, IND, PPM1D, Biology, Biophysics, Cancer, Pharmacokinetics, TYK2, Development, Probability, Artificial intelligence, Proteome, Pharmaceutical industry

Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter.

Key Points: 
  • Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter.
  • AtomNet also showed a remarkable ability to discover novel chemical matter, averaging over seven structurally distinct bioactive compounds per target.
  • Developed by Atomwise, AtomNet was the first deep neural network designed to predict the bioactivity of small molecules in structure-based drug discovery.
  • Our belief is structurally novel chemical matter increases the likelihood of developing first-in-class and best-in-class medicines that have the potential to transform patient care.

Analyses Find Patients With Polycythemia Vera (PV) Treated With BESREMi® (ropeginterferon alfa-2b) Had Increased Probability of Achieving Complete Hematologic Response

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Surgery, Clinical Trials, Cardiology, Biotechnology, Week, Polycythemia, CHR, ALT, Hematology, Patient, News, Safety, Probability, PV, Pharmaceutical industry

Writing and editorial support were funded by PharmaEssentia, however authors retained full editorial control and provided final approval on all content.

Key Points: 
  • Writing and editorial support were funded by PharmaEssentia, however authors retained full editorial control and provided final approval on all content.
  • Among key findings, patients with PV treated with ropeginterferon alfa-2b had an increased probability of achieving CHR and reducing JAK2V617F allele burden with acceptable safety risks.
  • The exposure–safety population was comprised of 49 patients from the Phase 2 Chinese study (A20-202).
  • The final exposure–CHR model structure for the A20-202 study demonstrated that ropeginterferon alfa-2b increases the probability of achieving CHR with its dose.

American Strategic Investment Co. Announces Fourth Quarter 2023 Results

Retrieved on: 
Monday, April 1, 2024
Commercial Building & Real Estate, Construction & Property, ASIC, Webcast, Internet, Tenant, Software, Depreciation, Probability, Security (finance)

The Company’s portfolio consisted of seven properties and comprised 1.2 million rentable square feet as of December 31, 2023.

Key Points: 
  • The Company’s portfolio consisted of seven properties and comprised 1.2 million rentable square feet as of December 31, 2023.
  • Portfolio metrics include:
    87% leased, compared to 83% at the end of fourth quarter 2022, with 6.5 years remaining weighted-average lease term
    As of December 31, 2023, the Company had $5.3 million of cash and cash equivalents(5).
  • As used herein, investment grade includes both actual investment grade ratings of the tenant or guarantor, if available, or implied investment grade.
  • Top 10 tenants are 59% actual investment grade rated and 20% implied investment grade rated.

Wolters Kluwer enters nursing test prep market with launch of Lippincott Ready for NCLEX

Retrieved on: 
Thursday, March 28, 2024
Other Professional Services, Legal, Other Education, Technology, Continuing, University, Finance, Training, Education, Accounting, General Health, Professional Services, Asset Management, Software, Nursing, Health, College, NCLEX, NCSBN, Undergraduate education, Learning, Environment, Knowledge, National Council, Student, Education minister, Nurse education, Wolters Kluwer, Curriculum, Multimedia, Probability

To help prepare nursing students for real-world practice, Wolters Kluwer Health today announces the launch of Lippincott Ready for NCLEX® , a complete test prep solution for the National Council Licensure Examination ( NCLEX ).

Key Points: 
  • To help prepare nursing students for real-world practice, Wolters Kluwer Health today announces the launch of Lippincott Ready for NCLEX® , a complete test prep solution for the National Council Licensure Examination ( NCLEX ).
  • View the full release here: https://www.businesswire.com/news/home/20240328576892/en/
    To help prepare nursing students for real-world practice, Wolters Kluwer Health announces the launch of Lippincott Ready for NCLEX®, a complete test prep solution for the National Council Licensure Examination (Graphic: Business Wire)
    “By combining deep educational and testing expertise from Lippincott®, NurseTim®, and NurseThink®, we are redefining the nursing education testing market with a one-stop solution for NCLEX success,” said Julie Stegman , Vice President, Wolters Kluwer Health Learning & Practice.
  • The new Lippincott Ready for NCLEX combines performance insights for the NCLEX exam plus adaptive learning tools that help improve performance, including Lippincott PassPoint and NurseThink® NCLEX-RN® Conceptual Review Guide.
  • Together with Lippincott® Partnership for Nursing Education and Testing , Wolters Kluwer further integrates NurseTim offerings into Lippincott’s full curriculum collection of educational products and services for leading U.S. prelicensure nursing programs.

Traders Have a Powerful New Tool With the Launch of the iFi AI Artificial Intelligence-Powered Stock Research Platform

Retrieved on: 
Wednesday, March 27, 2024
Apps, Applications, Technology, Finance, Fintech, Professional Services, Software, Data Analytics, Asset Management, Artificial Intelligence, Intelligence, Create, IBM, Partnership, Noise, App, Probability, ETF, AI, Medical device

None, that is, until today, with the introduction of iFi AI.

Key Points: 
  • None, that is, until today, with the introduction of iFi AI.
  • Alongside each forecasted return, iFi AI also provides an assigned Confidence Value, a specific numerical value showing iFi AI users the level of conviction the firm’s model has identified for each and every trade.
  • Says iFi AI Chief Executive Officer Ron Insana, “Knowing what to trade and when to trade it; that’s every trader’s holy grail.
  • “iFi AI is a transformative platform, better equipping traders to identify the most opportunistic moments to add to or discard from positions,” added Insana.

Vectara Launches Factual Consistency Score Powered by Upgraded Hughes Hallucination Evaluation Model to Enhance Transparency in GenAI Responses

Retrieved on: 
Tuesday, March 26, 2024
Data Management, Technology, Apps, Applications, Artificial Intelligence, Software, Consistency, Synthetic media, Yobi, Risk, RAG, Calibration, Ambiguity, Engineering, Hallucination, Partner, FCS, Probability, Generative, Insurance

The associated Hallucination Leaderboard is now the industry standard for how LLMs benchmark their average factual consistency.

Key Points: 
  • The associated Hallucination Leaderboard is now the industry standard for how LLMs benchmark their average factual consistency.
  • This innovative metric provides unprecedented visibility into the factual consistency of summarized responses within Vectara’s RAGaaS platform, empowering users to set personalized thresholds for response acceptance based on a detailed accuracy score.
  • Vectara mitigates this ambiguity for enterprises by providing a Factual Consistency Score grading the likelihood that the generated response is a hallucination or not.
  • "Integrating Vectara's Factual Consistency Score into the Yobi app will revolutionize how we handle AI transparency and accuracy for business use cases.

Kolibri Global Energy Inc. Announces Proved Reserves With Net Present Value of US$483 Million

Retrieved on: 
Thursday, March 21, 2024
Oil, Gas, Energy, Net, Growth, National instrument, PDP, TSX, SCOOP, KEI, Reserve, NSAI, Probability, NPV, Cryptocurrency

Kolibri Global Energy Inc. (the “Company” or “KEI”) (TSX: KEI), is providing the results of its December 31, 2023, independent reserves evaluation.

Key Points: 
  • Kolibri Global Energy Inc. (the “Company” or “KEI”) (TSX: KEI), is providing the results of its December 31, 2023, independent reserves evaluation.
  • Our percentage of PDP versus Total Proved reserves increased to 24% from 18% last year as we continued to convert our proved undeveloped reserves into cash generating PDP wells.
  • We are also pleased that the Net Present Value (“NPV”) of the PDP reserves increased by 11% even as the forecast pricing used in the reserve report decreased compared to the prior year.
  • “Our Proved Reserves value of US$482.6 million (NPV discounted at 10%), decreased by 6% from the 2022 independent reserves evaluation.

Profluent Secures $35M in Additional Funding and Key Industry Experts to Scale Foundational AI Models for Biomedicine and Tackle First Vertical in Gene Editing

Retrieved on: 
Thursday, March 21, 2024
Other Health, Software, Research, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Other Science, Health, AIX, Cas9, OpenAI, Gene editing, Insight Partners, Growth, Spotlight, General partnership, Salesforce, Nature Biotechnology, Gene, Spark Capital, AI, University, Tome, Nature, Protein engineering, Biology, Microbiology, CRISPR, De novo, ChatGPT, Therapy, Machine learning, Probability, Management

Profluent, an AI-first protein design company, today announced the close of additional funding to bring the total raised to $44M.

Key Points: 
  • Profluent, an AI-first protein design company, today announced the close of additional funding to bring the total raised to $44M.
  • “Our research at the forefront of AI has enabled Profluent to create large language models that begin to learn the blueprint of nature,” said Ali Madani, Profluent co-founder and Chief Executive Officer.
  • By first applying its platform to gene editing, the company showcases AI as the ideal interface for engineering complex biological systems.
  • Just as ChatGPT can write compelling essays and emails, Profluent has developed AI that designs entirely new and functional proteins.

Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases

Retrieved on: 
Thursday, March 21, 2024
Health, Infectious Diseases, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Farallon Capital, ARCH Venture Partners, Patient, Merck, Medicine, Investment, Therapy, OrbiMed, Machine learning, Probability, RTW, Pharmaceutical industry

Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount.

Key Points: 
  • Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount.
  • “At Mirador, we envision a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy,” said Mark C. McKenna, chairman and CEO of Mirador.
  • To accelerate development, Mirador utilizes Mirador360, its proprietary precision development engine that leverages recent breakthroughs in human genetics and cutting-edge data science.
  • Mirador360 also allows Mirador to develop diagnostics and stratify heterogeneous patient populations for precise clinical development.

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Retrieved on: 
Wednesday, March 20, 2024
Research, Mental Health, Medical Devices, FDA, Clinical Trials, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Principal, OSA, LivaNova, Obstructive sleep apnea, Somnolence, PLC, Patient, AHI, University, Trial of the century, LIVN, University of California, Randomized controlled trial, Safety, Probability, Food, Medical imaging

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation , has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation , has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated.
  • This means there is a greater than 97.5% probability that the OSPREY trial will successfully meet its primary endpoint.
  • LivaNova notified the U.S. Food and Drug Administration (FDA) and its partner trial sites of this significant milestone for the OSPREY study.
  • “We are pleased to have achieved this positive milestone for the OSPREY study,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova.